In multiple myeloma (MM), M3258 demonstrated potent, selective suppression of LMP7 activity, leading to durable inhibition of ubiquitinated protein turnover, apoptosis, and superior tumor control compared to broad-spectrum PIs such as bortezomib (64). Here, PSMB8 is linked to neoplasm.